Connection lost
Server error
Eisai, Inc. v. Sanofi Aventis U.S., LLC Case Brief
Why Top Law Students (And Those Aspiring to Be) Use LSD+ Briefs
Let's be real, law school is a marathon. Our exclusive Flash-to-Full case system is designed by Harvard Law School and MIT grads to match your pace: Quick summaries when you're slammed, detailed analysis when you need to go deep. Only LSD+ offers this kind of flexibility to genuinely fit your study flow.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: A dominant drug manufacturer’s market-share discount program was challenged by a competitor as de facto exclusive dealing. The court found the program lawful, reasoning that customers were not foreclosed from the market but simply chose the better economic deal, which is not an antitrust violation.
Legal Significance: This case clarifies that single-product loyalty discounts, even those offered by a monopolist, are generally lawful if they are above-cost and do not coerce customers. It distinguishes such discounts from the multi-product bundled rebates found unlawful in LePage’s Inc. v. 3M.
Eisai, Inc. v. Sanofi Aventis U.S., LLC Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
Sanofi Aventis (Sanofi) manufactured Lovenox, a dominant anticoagulant drug with over 80% market share and a unique FDA-approved cardiology indication that competitors lacked. Eisai, Inc. (Eisai) sold a competing drug, Fragmin. Sanofi offered hospitals a discount program for Lovenox with two key features. First, it provided substantial discounts (up to 30%) to hospitals that purchased at least 75% of their anticoagulant drugs from Sanofi; below this threshold, the discount was only 1%. Second, a formulary access clause required participating hospitals not to restrict access to Lovenox more than its competitors. Hospitals were not contractually obligated to meet the 75% threshold and could terminate the contract with 30 days’ notice. The only penalty for non-compliance was the loss of the higher discount. Eisai sued, alleging this program constituted a de facto exclusive dealing arrangement that unlawfully maintained Sanofi’s monopoly. Eisai’s expert argued Sanofi bundled hospitals’ “incontestable demand” for Lovenox (due to its unique indication) with their “contestable demand,” effectively foreclosing competitors.
Court Holding & Legal Precedent
Issue: Did a dominant pharmaceutical company’s program of market-share-based discounts and formulary access requirements for a single product constitute an unlawful exclusive dealing arrangement that substantially lessened competition under the rule of reason?
No. The court affirmed summary judgment for Sanofi, holding that Eisai failed Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
IRAC Legal Analysis
Complete IRAC Analysis for Higher Grades
IRAC (Issue, Rule, Analysis, Conclusion) is the exact format professors want to see in your exam answers. Our exclusive Flash-to-Full briefs combine holding, analysis, and rule statements formatted to match what A+ students produce in exams. These structured briefs help reinforce the essential legal reasoning patterns expected in law school.
Legal Issue
Did a dominant pharmaceutical company’s program of market-share-based discounts and formulary access requirements for a single product constitute an unlawful exclusive dealing arrangement that substantially lessened competition under the rule of reason?
Conclusion
The decision reinforces the high bar for proving de facto exclusive dealing, Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
Legal Rule
An exclusive dealing arrangement violates the antitrust laws under the rule of Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaeca
Legal Analysis
The court analyzed Sanofi's conduct under the rule of reason as a Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia de
Flash-to-Full Case Opinions
Flash Summary
- Holding: Affirmed summary judgment for defendant Sanofi; its market-share discount program
